Merck & Co. Acquires Viralytics for $394 Million
Merck & Co. has acquired oncology-focused biopharmaceutical company Viralytics to strengthen Merck's oncology pipeline.
On Feb. 21, 2018, Merck & Co. announced that it has acquired Viralytics, an oncology-focused biopharmaceutical company based in Sydney, Austrailia for $394 million.
The transaction has been set for AUD$1.75 cash (US$1.37) per Viralytics share. Merck reports that the proposed acquisition values the total issued shares in Viralytics at approximately AUD$502 million (US$394 million).
Upon completion of the transaction, Viralytics will become a wholly owned subsidiary of Merck, and Merck will gain full rights to Cavatak (is there an active ingredient name?), Viralytics’ investigational oncolytic immunotherapy, as stated by Merck. Cavatak is based on Viralytics’ proprietary formulation of an oncolytic virus that Merck says preferentially infects and terminates cancer cells. The drug is being evaluated in multiple Phase I and Phase II clinical trials, as both an intratumoral and intravenous agent, including in combination with Merck’s Keytruda (pembrolizumab), an immunotherapy blockbuster drug with 2017 sales of $3.8 billion.
In accordance with an agreement between Viralytics and a subsidiary of Merck, announced in November 2015, the companies are investigating the use of the Cavatak and Keytruda combination in melanoma, prostate, lung, and bladder cancers, according to Merck.
Merck reports that the board of directors of Viralytics unanimously recommends that its company’s shareholders vote in favor of the acquisition. The companies expect the transaction will be implemented by the second quarter of 2018, subject to a Viralytics’ shareholder vote and customary regulatory approvals.
“Viralytics’s approach of engaging the innate immune system to target and kill cancer cells complements our immuno-oncology strategy, which is focused on the rapid advancement of innovative monotherapy approaches and synergistic combinations to help the broadest range of cancer patients,” said Dr. Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories, in a company press release. “We are eager to further build on Viralytics’s science as we continue our efforts to harness the immune system to improve long-term disease control and survival outcomes for people with cancer.”
Source: Merck & Co.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
In Wake of Trump Tariffs, Lilly Plans New US Pharmaceutical Manufacturing Sites
February 26th 2025Previous domestic capital expansion commitments since 2020 had been made in Research Triangle Park and Concord, both in North Carolina; Kenosha County, Wisconsin; Lebanon, Indiana; and Lilly’s home city of Indianapolis.
Cosette Pharmaceuticals Adds to Dermatology and Women’s Health Portfolio with Mayne Pharma Purchase
Published: February 26th 2025 | Updated: February 26th 2025While the boards of directors of both companies have approved the transaction, it is not expected to close until the second quarter of 2025, as Mayne Pharma’s shareholders must still vote in favor of the acquisition.
FDA Approves First Treatment for Rare Lipid Storage Disease Cerebrotendinous Xanthomatosis
February 24th 2025Cerebrotendinous xanthomatosis, or CTX, is a metabolic disorder caused by a gene mutation that results in a deficiency of an important enzyme in the ability of the human body to break down fats.
